Canada Multiomics Market (2026-2031)
The Canada Multiomics Market was valued at $122.4 Million in 2026 and projected to reach to $194.4 Million by 2031, representing a compound annual growth rate of 9.7%. Canada's multiomics market is positioned for sustained growth through 2031, supported by the country's commitment to precision medicine and genomic research funding.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada Multiomics Market Trends and Insights
- This 9.7% compound annual growth rate reflects Canada's increasing adoption of integrated genomic, proteomic, and metabolomic technologies across research institutions and clinical settings.
- Canada's robust healthcare infrastructure and investment in precision medicine initiatives are driving demand for multiomics solutions that enable comprehensive biological analysis. The Canadian multiomics sector benefits from strong government funding for life sciences research and a growing number of academic medical centers implementing advanced diagnostic platforms.
- Canada's position as a leader in biotechnology innovation supports the expansion of multiomics applications in oncology, rare disease diagnosis, and personalized medicine.
- Between 2026 and 2031, Canada is expected to see increased commercialization of multiomics platforms and greater integration into clinical workflows, positioning the country as a key market within North America's broader multiomics landscape..
Key Market Statistics
- CAGR (2026-2031) 9.7% CAGR
- Market Size, 2026 ~USD 122.4 Million
- Forecast, 2031 ~USD 194.4 Million
- Country Canada
Canada Multiomics Market Overview
Market Valuation Growth :
Canada's multiomics market is valued at $122.4 million in 2026 and is projected to reach $194.4 million by 2031, representing a robust 58.9% total growth over the five-year forecast period.
Strong CAGR Performance :
With a 9.7% compound annual growth rate, Canada's multiomics market is expanding steadily, driven by increasing adoption of integrated genomic, proteomic, and metabolomic technologies across research and clinical institutions.
Healthcare Infrastructure Advantage :
Canada's advanced healthcare system and significant investment in precision medicine initiatives create a favorable environment for multiomics technology adoption and clinical implementation across provinces.
Research Institution Leadership :
Leading Canadian research centers and academic hospitals are increasingly integrating multiomics platforms for drug discovery, biomarker identification, and personalized treatment development.
Canada Multiomics Market Dynamics
- Academic institutions and healthcare providers are increasingly recognizing the value of integrated omics approaches for disease understanding and therapeutic development.
- The Canadian government's investment in life sciences infrastructure and the presence of world-class research facilities will continue to drive market expansion. Key growth drivers include rising adoption of multiomics in oncology, rare disease diagnosis, and pharmacogenomics applications.
- Collaboration between Canadian biotech companies, research institutions, and healthcare systems is accelerating technology implementation.
- As costs decrease and analytical capabilities improve, multiomics adoption is expected to expand beyond research settings into routine clinical diagnostics and personalized medicine programs across Canadian healthcare networks..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Canada's multiomics market is valued at $122.4 million in 2026 and will grow to $194.4 million by 2031, representing a 9.7% CAGR.
- Canada's strong healthcare infrastructure and government funding for life sciences research are primary drivers of multiomics adoption.
- Canadian academic medical centers and research institutions are increasingly implementing multiomics platforms for precision medicine applications.
- Canada's multiomics market is positioned for accelerated clinical integration and commercialization through 2031, supporting personalized diagnostics and treatment strategies.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
Canada Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Multiomics Technology Vendors : Manufacturers and software providers need Canada-specific market data to assess market opportunity, identify customer segments, and develop localized sales strategies for genomics, proteomics, and metabolomics platforms.
- Healthcare System Administrators : Canadian hospital networks and provincial health authorities require market insights to evaluate multiomics technology investments, understand adoption trends, and plan precision medicine program implementations.
- Biotech and Pharmaceutical Companies : Canadian and international biotech firms need market intelligence to guide R&D investments, identify partnership opportunities, and understand the competitive landscape for multiomics-driven drug discovery.
- Research Institution Leaders : Academic medical centers and research institutes need data on multiomics market trends to justify infrastructure investments, secure funding, and position their institutions as precision medicine leaders.
- Investment and Venture Capital Firms : Investors evaluating Canadian life sciences opportunities require market sizing and growth projections to assess portfolio companies, identify emerging opportunities, and guide funding decisions in the multiomics space.
Reasons to Buy this Report
- Canada-Specific Market Sizing : Access precise valuation data for Canada's multiomics market with verified 2026 baseline ($122.4M) and 2031 forecast ($194.4M), enabling accurate budget allocation and investment planning for Canadian operations.
- Regional Growth Trajectory Analysis : Understand Canada's 9.7% CAGR performance relative to global trends (12.3%), identifying unique growth drivers and market dynamics specific to Canadian healthcare, research, and biotech sectors.
- Provincial Market Insights : Gain intelligence on multiomics adoption patterns across Canadian provinces, healthcare systems, and research institutions to identify high-opportunity regions for product launches and partnerships.
- Competitive Positioning Strategy : Develop targeted go-to-market strategies for Canada by understanding local adoption rates, regulatory environment, and key stakeholder preferences in precision medicine and genomic research.
- Investment Decision Support : Make informed decisions on Canadian market entry, expansion, or acquisition opportunities with comprehensive data on market size, growth rates, and sector-specific trends through 2031.
Frequently asked questions
What is the current size of Canada's multiomics market?
Canada's multiomics market is estimated at $122.4 million in 2026 and is projected to reach $194.4 million by 2031.
What is the growth rate of Canada's multiomics market?
Canada's multiomics market is expected to grow at a compound annual growth rate (CAGR) of 9.7% from 2026 to 2031.
What factors are driving growth in Canada's multiomics market?
Key drivers include Canada's robust healthcare infrastructure, government funding for life sciences research, increasing adoption of precision medicine, and growing implementation of multiomics platforms in academic medical centers.
Which applications are leading Canada's multiomics market expansion?
Canada's multiomics market is expanding primarily in oncology diagnostics, rare disease identification, and personalized medicine applications across research and clinical settings.
How does Canada's multiomics market compare to North America?
Canada represents a significant segment of the North American multiomics market, with its 9.7% CAGR reflecting strong regional demand for integrated omics technologies and precision diagnostics.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- US Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- Japan Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
